Sangamo Therapeutics Inc (SGMO) reports significant progress in clinical trials and funding, despite facing regulatory uncertainties and cash management hurdles.

Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across ...

CEO Al Sandrock outlined several 2026 priorities in a discussion focused on the company’s tau-directed pipeline and its newer ...

Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across al ...

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and ...

It's my pleasure to be moderating this chat with the CEO of Voyager Therapeutics, Al Sandrock, who sure many folks know well from his current role and famous roles as prior. Al, maybe we can get into ...

First ZEVASKYN® commercial patient treatment completed in December -- ZEVASKYN launch momentum building in first quarter 2026 –- $191.4M in ...

Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research ...

Belief BioMed ("BBM") and Grand Life Sciences Group Co., Ltd. ("Grand Life Sciences") today announced an exclusive collaboration agreement. Under the agreement, Belief BioMed will grant Grand Life ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company’s launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous ...

Detailed price information for Theralase Technologies Inc. (TLT-X) from The Globe and Mail including charting and trades.